07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Blackfield, AstraZeneca deal

Blackfield will use its genomics technologies and computational biology capabilities to validate preclinical models for an undisclosed cancer program from AstraZeneca. The companies could not be reached for details. Blackfield AG , Cologne, Germany  ...
07:00 , Mar 11, 2013 |  BioCentury  |  Emerging Company Profile

Blackfield: Mining cancer genomes

Blackfield AG is leveraging the genome analysis experience and oncology expertise of its academic founders to offer a one-stop shop for cancer genomics-based drug discovery services. The University of Cologne spinout was founded last year...
08:00 , Feb 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Promoting telomerase

Two independent teams have identified activating mutations in the promoter of telomerase reverse transcriptase that occur in more than 70% of melanoma cases. 1,2 The findings highlight the still-untapped potential of analyzing noncoding regions of...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Small cell lung cancer (SCLC) Aurora kinase B (AURKB; aurora-B); c-Myc (MYC) A cell screening study suggests aurora-B inhibitors could help treat SCLCs with MYC...